Eli Lilly Vs. Novo Nordisk: Which Is The Better Bargain For Investors
Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain ...
Novo Holdings participates in €23 million Series A for Tribune Therapeutics to advance next-generation anti-fibrotic therapies
Novo Holdings today announced its participation in a €23 million Series A round for Tribune Therapeutics ('Tribune'). The round was led by new investor LifeArc Ventures and joined by Novo Holdings, ...
Business Insider6d
Augustine Therapeutics raises oversubscribed EUR 78 million / USD 85 million Series A financing round
Augustine Therapeutics raises oversubscribed EUR 78 million / USD 85 million Series A financing round Novo Holdings and Jeito Capital co-led the deal, supported by Asabys Partners and existing ...
The National Law Review2d
Change In Australian Shareholder Registry Services
Shareholders with any queries in relation to their Novo holding are advised to contact Automic at [email protected] or on 1300 288 664 (within Australia) or +61 2 9698 5414 (outside ...
The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist
The issuer is solely responsible for the content of this announcement.
Mena FN4d
Novo Holdings Participates In €23 Million Series A For Tribune Therapeutics To Advance Next-Generation Anti-Fibrotic Therapies
The round was led by new investor LifeArc Ventures and joined by Novo Holdings, HealthCap, Innovestor's Life Science Fund and Inven2 as well as new Series A investors Industrifonden and Investinor.